Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Montalescot G, et al. N Engl J Med. 2001 Jun 21;344(25):1895-903. doi: 10.1056/NEJM200106213442503. N Engl J Med. 2001. PMID: 11419426 Free article. Clinical Trial.
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Kereiakes DJ, et al. Among authors: montalescot g. Am Heart J. 2002 Oct;144(4):615-24. doi: 10.1067/mhj.2002.124405. Am Heart J. 2002. PMID: 12360156 Review.
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E; Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Ellis SG, et al. Among authors: montalescot g. Am Heart J. 2004 Apr;147(4):E16. doi: 10.1016/j.ahj.2003.07.025. Am Heart J. 2004. PMID: 15077099 Clinical Trial.
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, Laufenberg CV, Klutman M, Gowda N, Gulba D; GRACE Investigators. Collet JP, et al. Among authors: montalescot g. Eur Heart J. 2005 Nov;26(21):2285-93. doi: 10.1093/eurheartj/ehi337. Epub 2005 Jun 2. Eur Heart J. 2005. PMID: 15932908 Clinical Trial.
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E; EARLY ACS Steering Committee. Giugliano RP, et al. Among authors: montalescot g. Am Heart J. 2005 Jun;149(6):994-1002. doi: 10.1016/j.ahj.2005.03.029. Am Heart J. 2005. PMID: 15976780
813 results